F
LIVE

Serial Number

88028459

Owner

Factor Bioscience LLC

Attorney

Rachelle A. Dubow, Esq.

First Use Date

Nov 19, 2019

Filing Date

Jul 6, 2018

Add to watchlist:

No watchlists yet
View on USPTO

F Trademark

Serial Number: 88028459 • Registration: 6008689

F is a trademark filed by Factor Bioscience LLC on July 6, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Factor Bioscience LLC (7 trademarks)

Suite 17B
Cambridge, MA 02141

Entity Type: 16

Trademark Details

Filing Date

July 6, 2018

Registration Date

March 10, 2020

First Use Anywhere

November 19, 2019

First Use in Commerce

November 19, 2019

Published for Opposition

June 18, 2019

Goods & Services

Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments

Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease

Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering

Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 10, 2025 REM1
REGISTERED-PRINCIPAL REGISTER
Mar 10, 2020 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Feb 5, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 4, 2020 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Dec 29, 2019 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 29, 2019 AITU
USE AMENDMENT FILED
Dec 18, 2019 IUAF
TEAS STATEMENT OF USE RECEIVED
Dec 18, 2019 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 13, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 18, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jun 18, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 29, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 10, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
May 9, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 9, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
May 9, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 9, 2019 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 10, 2019 GNFN
FINAL REFUSAL E-MAILED
Apr 10, 2019 GNFR
FINAL REFUSAL WRITTEN
Apr 10, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 19, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 19, 2019 CRFA
ASSIGNED TO LIE
Feb 18, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 12, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 27, 2018 GNRN
NON-FINAL ACTION E-MAILED
Oct 27, 2018 GNRT
NON-FINAL ACTION WRITTEN
Oct 27, 2018 CNRT
ASSIGNED TO EXAMINER
Oct 25, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 12, 2018 NWOS
NEW APPLICATION ENTERED
Jul 10, 2018 NWAP